The FDA approved Leqembi (lecanemab-irmb), the second of a new category of medications approved for Alzheimer’s disease that target the fundamental pathophysiol| U.S. Food and Drug Administration
Alzheimer’s disease is a progressive, irreversible brain disorder that affects memory, thinking, and language skills.| U.S. Food and Drug Administration